Relazioni brevi
V. 14 (2026)
Studio di follow-up di due anni sulla comparsa di autoanticorpi antinucleo e manifestazioni cliniche in una popolazione di operatori sanitari ospedalieri dopo vaccinazione anti-SARS-CoV-2
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Pubblicato: 5 maggio 2026
47
Visite
30
Downloads
Autori
Background: sebbene la vaccinazione anti-COVID-19 sia stata fondamentale nel controllo della pandemia, sono emerse preoccupazioni circa possibili eventi avversi autoimmuni.
L’obiettivo era di valutare, in un follow-up di due anni, la comparsa di anticorpi antinucleo (ANA) e di sintomi clinici correlati in operatori sanitari vaccinati con BNT162b2 o mRNA-1273.
Materiali e Metodi: sono stati arruolati 52 operatori sanitari che avevano ricevuto almeno tre dosi di vaccino a mRNA; 35 hanno completato i prelievi al basale (T0) e dopo 3 (T1), 12 (T2) e 24 mesi (T3). Gli ANA sono stati valutati mediante immunofluorescenza indiretta su cellule HEp-2.
Risultati: nell’analisi finale sono stati inclusi 17 soggetti ANA-negativi, rimasti non infetti da SARS-CoV-2 durante il follow-up. Dieci hanno sviluppato ANA de novo in tempi diversi; cinque sono risultati positivi a T1, T2 e T3, senza sintomi autoimmuni clinicamente significativi.
Conclusioni: gli ANA possono comparire dopo vaccinazione anti-COVID-19, ma senza manifestazioni cliniche associate.
Downloads
La data di download non è ancora disponibile.
Citations
1.Guo M, Liu X, Chen X, Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun Rev 2023;22:103340.
2.Meslé MMI, Brown J, Mook P, et al. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study. Lancet Respir Med 2024;12:714-27.
3.Mobasheri L, Nasirpour MH, Masoumi E, et al. SARS-CoV-2 triggering autoimmune diseases. Cytokine 2022;154:155873.
4.Zebardast A, Hasanzadeh A, Ebrahimian Shiadeh SA, et al. COVID-19: a trigger of autoimmune diseases. Cell Biol Int 2023;47:848-58.
5.Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022;165:386-401.
6.Sacchi MC, Pelazza C, Bertolotti M, et al. The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study. Autoimmunity 2023;56:2229072.
7.Dotan A, Muller S, Kanduc D, et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021;20:102792.
8.Rodríguez Y, Rojas M, Beltrán S, et al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun 2022;132:102898.
9.Borghi MO, Bombaci M, Bodio C, et al. Anti-phospholipid antibodies and coronavirus disease 2019: vaccination does not trigger early autoantibody production in healthcare workers. Front Immunol 2022;13:930074.
10.Safary A, Esalatmanesh K, Eftekharsadat AT, et al. Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination. Int Immunopharmacol 2022;110:109061.
11.Gasparotto M, Bindoli S, Padoan R, et al. New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort. Clin Exp Rheumatol 2023;41:642-8.
12.Olivieri B, Betterle C, Zanoni G. Vaccinations and Autoimmune Diseases. Vaccines (Basel) 2021;9:815.
13.Toussirot É, Bereau M. Vaccination and Induction of Autoimmune Diseases. Inflamm Allergy Drug Targets 2015;14:94-8.
14.Bieber K, Hundt JE, Yu X, et al. Autoimmune pre-disease. Autoimmunity Reviews 2023;22:103236.
15.Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev 2021;20:102743.
16.Thurm C, Reinhold A, Borucki K, et al. Homologous and heterologous anti-COVID-19 vaccination does not induce new-onset formation of autoantibodies typically accompanying lupus erythematodes, rheumatoid arthritis, celiac disease and antiphospholipid syndrome. Vaccines (Basel) 2022;10:333.
17.Gazitt T, Eviatar T, Shear J, et al. Development of autoantibodies following BNT162b2 mRNA COVID-19 vaccination and their association with disease flares in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and the general population: results of 1-year prospective follow-up study. Vaccines (Basel) 2023;11:476.
18.Noureldine HA, Maamari J, El Helou MO, et al. The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels. Immunol Res 2022;70:800-10.
19.Blank RB, Haberman RH, Qian K, et al. Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis. Rheumatology (Oxford) 2022;62:467-72.
20.Świerkot J, Madej M, Szmyrka M, et al. The risk of autoimmunity development following mRNA COVID-19 vaccination. Viruses 2022;14:2655.
Come citare
Studio di follow-up di due anni sulla comparsa di autoanticorpi antinucleo e manifestazioni cliniche in una popolazione di operatori sanitari ospedalieri dopo vaccinazione anti-SARS-CoV-2. (2026). Working Paper of Public Health, 14(1). https://doi.org/10.4081/wpph.2026.10881
Copyright (c) 2026 Maria Cristina Sacchi, Carolina Pelazza, Lisa Agatea, Piera De Gaspari, Daniele Ielo, Marinella Bertolotti, Paolo Stobbione, Tatiana Bolgeo, Daria Valentini, Piero Novel, Andrea Piccinini, Maria Matilde Ciriello
Questo volume è pubblicato con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
